Search research articles
Contact Us
Filters
Showing results (61-70 of 150) with videos related to
Page
of 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Mesothelin expression in human lung cancer
Mitchell Ho, Tapan K Bera, Mark C Willingham, et al.
Oncotarget
|
May 12, 2016
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
Ronit Mazor, Masanori Onda, Dong Park, et al.
JCO Precision Oncology
|
October 30, 2018
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma
Liang Cao, Yunkai Yu, Anish Thomas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 12, 2009
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Raffit Hassan, Charles Schweizer, Kun F Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2005
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin
Junko Yokokawa, Claudia Palena, Philip Arlen, et al.
Cancer Research
|
January 28, 2010
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake
Yujian Zhang, Johanna K Hansen, Laiman Xiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2002
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro
Raffit Hassan, Megan R Lerner, Doris Benbrook, et al.
Anticancer Research
|
December 11, 2012
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P
Jingli Zhang, Shuo Qiu, Yujian Zhang, et al.
Molecular Cancer Therapeutics
|
November 9, 2012
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity
John E Weldon, Laiman Xiang, Jingli Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2020
<sup>18</sup>F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis-The Central Role of Volume
James C Reynolds, Roberto Maass-Moreno, Anish Thomas, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 150) with videos related to
Sort By:
Page
of 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2007
Mesothelin expression in human lung cancer
Mitchell Ho, Tapan K Bera, Mark C Willingham, et al.
Oncotarget
|
May 12, 2016
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
Ronit Mazor, Masanori Onda, Dong Park, et al.
JCO Precision Oncology
|
October 30, 2018
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma
Liang Cao, Yunkai Yu, Anish Thomas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 12, 2009
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Raffit Hassan, Charles Schweizer, Kun F Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2005
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin
Junko Yokokawa, Claudia Palena, Philip Arlen, et al.
Cancer Research
|
January 28, 2010
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake
Yujian Zhang, Johanna K Hansen, Laiman Xiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2002
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro
Raffit Hassan, Megan R Lerner, Doris Benbrook, et al.
Anticancer Research
|
December 11, 2012
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P
Jingli Zhang, Shuo Qiu, Yujian Zhang, et al.
Molecular Cancer Therapeutics
|
November 9, 2012
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity
John E Weldon, Laiman Xiang, Jingli Zhang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2020
<sup>18</sup>F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis-The Central Role of Volume
James C Reynolds, Roberto Maass-Moreno, Anish Thomas, et al.
Page
of 15